rabbit anti human p38 mapk d13e1 antibody  (Cell Signaling Technology Inc)

Journal: Scientific reports

Article Title: Crotonylation deficiency of S100A7 K49 promotes psoriatic keratinocyte proliferation through enhanced interaction with RAGE.

doi: 10.1038/s41598-025-96874-y

Figure Lengend Snippet: Fig. 5. S100A7 K49 crotonylation deficiency activates the AKT/mTOR pathway. (a) Western blotting of phospho-AKT (p-AKT S473), total AKT, phospho-mTOR (p-mTOR S2448), and total mTOR in keratinocytes transfected with S100A7-Wt/K49A. n = 2 per group. (b-c) The levels of expression (b) and phosphorylation (c) of ERK, p38, AKT, and mTOR in keratinocytes. n = 3 per group. (d) The effect of mTOR inhibitor, rapamycin, on the extracellular acidification ratio (ECAR) in keratinocytes. n = 4 per group. (e-h) The effect of mTOR inhibitor, rapamycin, on cell viability (e), glucose consumption (f), lactate production (g), and relative lactate dehydrogenase activity (h) in keratinocytes. n > 4 per group. (i) The effect of mTOR inhibitor, MTI-31, on the extracellular acidification ratio (ECAR) in keratinocytes. n = 4 per group. (j-m) The influence of mTOR inhibitor, MTI-31, on cell viability (j), glucose consumption (k), lactate production (l), and relative lactate dehydrogenase activity (m) in keratinocytes. n = 4 per group. * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

Article Snippet: Antibodies against p38 MAPK (D13E1) and phospho-p38 MAPK (D3F9) were derived from Cell Signaling Technology (Massachusetts, USA).

Techniques: Western Blot, Transfection, Expressing, Phospho-proteomics, Activity Assay

Journal: Cancer Cell International

Article Title: Thonzonium bromide inhibits progression of malignant pleural mesothelioma through regulation of ERK1/2 and p38 pathways and mitochondrial uncoupling

doi: 10.1186/s12935-024-03400-7

Figure Lengend Snippet: Effects of TB on ERK1/2 and p38 phosphorylation and BAX. Western blot analysis of the protein expression induced by TB (1 μM) at 24 h (for ERK 1/2 and p38) or 48 h (for BAX) post- treatment. β-Tubulin was used as reference. The picture is representative of one of two experiments, while the histograms were generated by quantifying blots from both experiments. The histograms report (Y-axis) the ratio (R) of the measurements obtained with Image Lab Software for (A) ERK 1/2 (Phospho-ERK/total ERK), (B) p38 (P-p38/total p38), and (C) BAX (BAX/β-Tubulin) relative to the controls (DMSO, the vehicle, shown as a dotted line) in MeT-5A, Mero-14, Mero-25, Ren, NCI-H28, and MSTO-211H cell lines (X-axis). Data are expressed as mean ± standard error and the statistical significance ( p <0.05) of the comparisons between controls and treatments is indicated by the asterisk (*)

Article Snippet: We bought from Cell Signaling Technology (Danvers, MA, USA) the primary antibodies for ERK1/2 (#4695T, p44/42 MAPK (Erk1/2) (137F5) Monoclonal Rabbit), phospho-ERK1/2 (#4370S, Phospho-p44/42 MAPK (Erk1/2 - Thr202/Tyr204 (D13.14.4E) XP® Monoclonal Rabbit), p38 (#8690, p38 MAPK (D13E1) XP® Rabbit mAb), phospho-p38 (#4511, Phospho-p38 MAPK - Thr180/Tyr182 (D3F9) XP® Rabbit mAb).

Techniques: Phospho-proteomics, Western Blot, Expressing, Generated, Software

Journal: International Journal of Molecular Sciences

Article Title: Erk Inhibition as a Promising Therapeutic Strategy for High IL-8-Secreting and Low SPTAN1-Expressing Colorectal Cancer

doi: 10.3390/ijms25115658

Figure Lengend Snippet: Used primary antibodies and target proteins.

Article Snippet: p38 MAPK (D13E1) , p38 (43 kDa) , 1:1000 , Cell Signaling Technology, Beverly, MA, USA.

Techniques: Molecular Weight